ISRCTN16723909进行中（未招募）未知
Phase III randomised controlled trial of Positive Choices: a whole-school social-marketing intervention to promote sexual health and reduce health inequalities
ondon School of Hygiene & Tropical Medicine0 个研究点目标入组 6,970 人开始时间: 2021年9月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6,970
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Students aged 12-16 years
- •2. Deemed competent to consent by schools
- •3. Moving from year 8 into year 11 during the trial
- •4. In English secondary schools (including faith schools, free schools, academies and private schools) excluding pupil referral units, schools for those with special educational needs and disabilities, and schools with poor Ofsted (government school inspectorate) inspections
排除标准
- •1. Students not deemed competent to consent by schools or students in pupil referral units
- •2. Schools for those with special educational needs and disabilities
- •3. Schools with poor Ofsted inspections
研究者
相似试验
进行中（未招募）
1 期
EMT2: EPA for Metastasis TrialColorectal cancer liver metastasesMedDRA version: 20.0Level: LLTClassification code 10007095Term: Cancer of liver, secondarySystem Organ Class: 100000004864EUCTR2016-000628-24-GBniversity of Leeds448
进行中（未招募）
1 期
Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV melanomaEUCTR2005-000941-12-GBOnyx Pharmaceuticals, Inc.
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-BEniversity Medicine Goettingen274
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-ATniversity Medicine Goettingen276
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 years ICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1 Level: LLT Classification code 10002464 Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1 Level: LLT Classification code 10025632 Term: Malignant lymphomaEUCTR2007-000821-23-FRniversity Medicine Goettingen274